Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
Real-time Quote. Real-time Tradegate - 01/23 01:24:00 pm
71.355 EUR   +0.74%
09:44a Biotech indexes gain on deals
08:48a Drug Firms Bet Billions on Biotech -- WSJ
07:11a SANOFI : snaps up US biotech in $12bn deal
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:35pm CET
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.

1/2

The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 [email protected] [email protected]

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:14p SANOFI : to Acquire Bioverativ for $11.6 Billion
11:30a SANOFI : to buy Bioverativ for $11.6bn
09:44a Biotech indexes gain on deals
09:38a SANOFI : Ex-DOH chief Ona denies joining Aquino in Sanofi meeting
09:20a SANOFI : Gatchalian grills Garin on price talks with Sanofi in June 2015
09:18a SANOFI : Facing Threat From Generics, Moves to Buy Hemophilia Drug Maker
09:17a SANOFI : in pact to acquire US biotech haemophila drugs maker Bioverativ for 11...
08:48a Drug Firms Bet Billions on Biotech -- WSJ
07:11a SANOFI : snaps up US biotech in $12bn deal
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
More news
News from SeekingAlpha
03:52a U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 22, 2018
01/22 Biotech Forum Daily Digest For January 21st
01/22 PREMARKET GAINERS AS OF 9 : 05 am (1/22/2018)
01/22 Regeneron's Dupixent OK'd in Japan for atopic dermatitis
01/22 WALL STREET BREAKFAST : Futures Slip As Shutdown Continues
Financials (€)
Sales 2017 35 679 M
EBIT 2017 9 098 M
Net income 2017 7 967 M
Debt 2017 5 761 M
Yield 2017 4,20%
P/E ratio 2017 11,20
P/E ratio 2018 15,57
EV / Sales 2017 2,67x
EV / Sales 2018 2,63x
Capitalization 89 468 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 83,8 €
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI1.53%109 634
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132